Cornerstone Capital Management Holdings LLC. decreased its stake in shares of Icon Plc (NASDAQ:ICLR) by 8.3% during the fourth quarter, HoldingsChannel reports. The firm owned 375,228 shares of the medical research company’s stock after selling 34,168 shares during the quarter. Cornerstone Capital Management Holdings LLC.’s holdings in Icon were worth $42,081,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in Icon during the 3rd quarter valued at about $148,000. Financial Gravity Companies Inc. purchased a new position in Icon during the 4th quarter valued at about $144,000. C M Bidwell & Associates Ltd. purchased a new position in Icon during the 4th quarter valued at about $196,000. Advisor Partners LLC purchased a new position in Icon during the 4th quarter valued at about $201,000. Finally, Dean Capital Investments Management LLC purchased a new position in Icon during the 4th quarter valued at about $203,000. 90.50% of the stock is currently owned by hedge funds and other institutional investors.
Icon Plc (NASDAQ:ICLR) opened at $123.90 on Tuesday. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.29. The stock has a market cap of $6,608.16, a PE ratio of 22.71, a price-to-earnings-growth ratio of 1.73 and a beta of 0.45. Icon Plc has a twelve month low of $76.46 and a twelve month high of $124.65.
ICLR has been the subject of a number of recent research reports. SunTrust Banks reissued a “buy” rating and set a $133.00 price target on shares of Icon in a research report on Monday, January 22nd. KeyCorp reaffirmed a “buy” rating and issued a $130.00 target price on shares of Icon in a report on Thursday, January 11th. ValuEngine raised shares of Icon from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. Zacks Investment Research raised shares of Icon from a “hold” rating to a “buy” rating and set a $127.00 target price for the company in a report on Wednesday, December 27th. Finally, Credit Suisse Group raised shares of Icon to a “buy” rating and set a $131.00 target price for the company in a report on Friday, February 16th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Icon presently has a consensus rating of “Buy” and a consensus price target of $126.00.
TRADEMARK VIOLATION WARNING: This article was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://sportsperspectives.com/2018/03/13/cornerstone-capital-management-holdings-llc-cuts-stake-in-icon-plc-iclr.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.